Large Market Opportunity

Approx. $4 Billion aggregate US/EU market opportunity in stroke/brain injury for Vision Restoration Therapy (VRT) and NeuroEyeCoach with up to approx. $13 Billion worldwide. Estimated $700 Million market opportunity for VBAS family of devices.

High and Stable Gross Profit Margins

Gross profit margin of 80%+

Product And Technologies Validated By Independent Practitioners And Published Clinical Studies

VBAS, is a best-in-class medical device whose acceptance is being driven by extensive clinical data supporting its clinical superiority, including 10 peer reviewed papers and 4 other clinical papers/posters. 8 clinical papers published or presented in 2015 and 2016 alone.

NovaVision’s products and therapies are used by rehabilitation centers, clinics and physicians in the US and Europe. VRT’s efficacy is supported by 15 years of research and 20 clinical studies and NeuroEyeCoach by several decades of research and 13 studies with over 500 patients. A new peer reviewed study on NeuroEyeCoach (Oct 2016) concluded: “NeuroEyeCoach is an effective compensatory approach for those with homonymous visual field loss. The training led to faster visual search times, reduction in the number of errors made, and improvements in reported activities of daily living”.

Limited Competition Due To Significant Barriers to Entry

  • VRT is the only FDA-cleared therapy for restoration of vision loss as the result of stroke or brain damage. NeuroEyeCoach also registered with FDA and both have CE Marking for Europe.

  • VBAS has regulatory approval in the U.S., E.U., and other key markets including Brazil, Canada, China and Japan.

  • Robust Patent Estate. Our patent suite spans 70 granted and pending patents globally.

  • Well established global footprint.

Management With Significant Personal Investment

Clear alignment of shareholder and management interests with our executives having invested over $4M and waiving cash compensation in favor of equity in Vycor Medical.